>
Switch to:

Biomarin Pharmaceutical Median PS Value

: $126.01 (As of Today)
View and export this data going back to 1999. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Biomarin Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2021 was $10.059. Biomarin Pharmaceutical's 10-Year median PS Ratio is 12.5271. Therefore, the Median PS Value for today is $126.01.

As of today (2021-12-08), Biomarin Pharmaceutical's share price is $86.12. Biomarin Pharmaceutical's Median PS Value is $126.01. Therefore, Biomarin Pharmaceutical's Price to Median PS Value for today is 0.68.

The historical rank and industry rank for Biomarin Pharmaceutical's Median PS Value or its related term are showing as below:

NAS:BMRN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16   Med: 0.82   Max: 1.63
Current: 0.68

0.16
1.63

During the past 13 years, the highest Price to Median PS Value of Biomarin Pharmaceutical was 1.63. The lowest was 0.16. And the median was 0.82.

NAS:BMRN's Price-to-Median-PS-Value is ranked higher than
64% of the 221 Companies
in the Biotechnology industry.

( Industry Median: 0.87 vs. NAS:BMRN: 0.68 )

Biomarin Pharmaceutical Median PS Value Historical Data

The historical data trend for Biomarin Pharmaceutical's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Median PS Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.75 97.82 104.03 116.54 124.72

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Median PS Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 125.29 124.72 124.15 128.28 126.01

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Median PS Value, along with its competitors' market caps and Median PS Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biomarin Pharmaceutical Median PS Value Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Median PS Value distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Median PS Value falls into.



Biomarin Pharmaceutical Median PS Value Calculation

Biomarin Pharmaceutical's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=10.059*12.5271
=126.01

10-Year Median PS Ratio is 12.5271.
Biomarin Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.059.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical  (NAS:BMRN) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Biomarin Pharmaceutical's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=86.12/126.01
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical Median PS Value Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)